PHARMASSET - "IFN-free Oral Option" for HCV- Sharing the Big Pie!
Pharmasset (VRUS) may enjoy the first mover advantage in the race to offer the first “IFN free all oral option” to HCV pts. However the window of opportunity will be brief as data presented at AASLD ‘11 highlighted multiple new serious contenders. VRUS can also tap the ROW opportunity as its drug is efficacious in other genotypes too. Till date key drug has remained unpartnered. Who all can be the more likely contender? For more details, please read our report released on Nov. 16th, 2011 on VRUS titled “IFN-free Oral Option” for HCV- Sharing the Big Pie!
COMPANIES MENTIONED
PHARMASSET
PHARMASSET
